Allogeneic Transplantation in Turkey

Which Diseases May Require Allogeneic Stem Cell Transplantation?

Allogeneic transplantation may be considered for selected blood cancers, marrow disorders, inherited conditions, and serious blood-forming system diseases.

• Acute leukemias: Selected AML and ALL pathways can include allogeneic transplantation according to disease risk and response.

• Myelodysplastic disorders: Some patients may undergo transplant evaluation when disease characteristics support this treatment approach.

• Aplastic anemia: Severe marrow failure can lead to allogeneic transplant assessment in appropriate patients.

• Hemoglobin disorders: Selected inherited blood diseases can be considered for donor stem cell transplantation.

• Other hematologic diseases: Individual transplant indications depend on diagnosis, disease status, previous therapy, and available alternatives.

A diagnosis alone does not determine eligibility. Transplant teams must evaluate expected benefits, risks, donor options, and individual health factors.

How Does HLA Matching Work for Allogeneic Transplantation in Turkey?

HLA matching compares important immune-system markers between the patient and potential stem cell donors. HLA stands for human leukocyte antigen. These markers help the immune system distinguish the body’s cells from foreign material. Transplant teams may first evaluate suitable siblings or other relatives. An unrelated donor search can follow when an appropriate related donor is unavailable. Haploidentical relatives provide another donor pathway for selected patients. Ankara Bilkent City Hospital documents matched siblings, unrelated donors, and haploidentical donors within its allogeneic program. Blood group alone cannot determine stem cell compatibility. Donor health and additional transplant factors also influence selection.

What Is TÜRKÖK and How Can It Support an Unrelated Donor Search?

TÜRKÖK is Turkey’s national system for coordinating hematopoietic stem cell donor searches and related transplantation processes. Turkey’s Ministry of Health established TÜRKÖK in 2015. Ministry information states that the system joined the World Marrow Donor Association in 2017. An unrelated donor search can become relevant when no suitable family donor is identified. Turkish transplant centers also document access to domestic and overseas donor-search pathways. However, registration does not guarantee a compatible donor. HLA characteristics and other donor factors determine whether a candidate can proceed. The transplant center manages the search according to the individual patient’s clinical requirements.

What Happens Before Donor Stem Cells Are Infused?

Patients receive medical assessment and conditioning before donor stem cells can be infused during an allogeneic transplant. Doctors first reassess the underlying disease and previous treatments. Blood tests evaluate counts, kidney function, liver function, and relevant infection risks. Heart and lung assessments may also be required. The donor undergoes a separate suitability assessment before cell collection. Conditioning usually involves chemotherapy and sometimes radiation therapy. It helps prepare the body for donor stem cells and reduces rejection risk. The intensity varies between transplant protocols. Doctors then infuse the donor cells intravenously and begin close monitoring for engraftment and early complications.

What Is the Difference Between Graft-Versus-Leukemia and Graft-Versus-Host Disease?

Graft-versus-leukemia and graft-versus-host disease are different immune effects created by donor cells after allogeneic transplantation. The graft-versus-leukemia effect occurs when donor immune cells recognize and attack remaining leukemia cells. NCI also uses the broader term graft-versus-tumor effect. GVHD occurs when donor immune cells attack healthy recipient tissues instead. The skin, gastrointestinal tract, liver, and other organs can become involved. This creates an important biological balance within allogeneic transplantation. The same donor-derived immune system can contribute to cancer control and transplant complications. Doctors therefore use preventive and treatment strategies to manage clinically important GVHD.

What Is Chimerism Monitoring After Allogeneic Transplantation?

Chimerism monitoring measures the relative contribution of donor and recipient blood-forming cells after allogeneic transplantation. Successful engraftment can produce increasing donor-derived blood production. Some transplant programs use genetic testing to measure donor chimerism after transplantation. NCI transplant protocols document short tandem repeat testing for this purpose. Mixed chimerism means donor and recipient cells remain detectable together. The significance depends on the disease, transplant approach, cell population, and timing. Chimerism should therefore not be interpreted as a simple pass-or-fail result. Transplant teams combine it with blood counts, disease testing, clinical findings, and other post-transplant information.

Is Engraftment the Same as Complete Immune Recovery?

No, engraftment and complete immune recovery describe different stages after an allogeneic stem cell transplant. Engraftment means donor stem cells have begun establishing new blood production. Doctors often monitor neutrophils, platelets, and other blood cells during this phase. Immune recovery continues after blood production begins. NCI notes that immune recovery can take one to two years after allogeneic transplantation. Individual recovery can differ substantially. GVHD and continuing immunosuppressive therapy can further affect immune function. Patients may therefore remain vulnerable to infections after blood counts improve. Infection precautions, vaccination planning, and specialist follow-up can continue well beyond early engraftment.

Which Complications Require Monitoring After Allogeneic Transplantation?

Allogeneic transplantation requires monitoring for immune, infectious, graft-related, and treatment-related complications throughout recovery.

• GVHD: Donor immune cells can attack healthy recipient tissues after transplantation.

• Infection: Conditioning and immunosuppression can increase vulnerability to bacterial, viral, and fungal infections.

• Graft problems: Donor cells can establish blood production slowly or inadequately in some circumstances.

• Organ toxicity: Conditioning and post-transplant medicines can affect several organs.

• Late effects: Longer-term follow-up can address endocrine, fertility, bone, lung, cardiovascular, and secondary cancer concerns.

The individual risk profile depends on donor type, conditioning, diagnosis, previous therapies, GVHD, and post-transplant medication requirements.

Why Can Vaccination Be Needed Again After Allogeneic Transplantation?

Revaccination can be necessary because allogeneic transplantation can reduce immunity established by vaccinations received before the transplant. CDC guidance recommends renewed vaccination schedules after hematopoietic cell transplantation. The schedule depends on vaccine type, immune recovery, and continuing immunosuppressive treatment. For example, CDC recommends a new Hib series after successful transplantation regardless of previous vaccination history. Live vaccines require more restrictive clinical assessment. Patients with active GVHD or continuing immunosuppression may need modified timing. International patients should therefore obtain a written revaccination plan before transferring care home. Previous vaccination records alone cannot define post-transplant protection.

What Should International Patients Verify Before Allogeneic Transplantation in Turkey?

International patients should verify transplant eligibility, donor arrangements, regulatory status, medical records, and long-term follow-up before traveling. Complete records should include pathology, marrow findings, molecular results, previous treatment, and recent laboratory information. Donor HLA records should also be provided when testing has already occurred. The Turkish Ministry of Health publishes authorized international health-tourism providers. Its current provider page is dated July 28, 2026. Health-tourism authorization does not guarantee transplant eligibility or clinical outcomes. Patients should separately confirm the required allogeneic transplant program. Emergency care and post-discharge monitoring should also be arranged before international travel.

What Do Turkey’s 2026 Health-Tourism Rules Mean for International Transplant Patients?

Turkey’s current health-tourism rules require international healthcare services to operate within Ministry authorization and applicable accreditation requirements. A Ministry notice dated May 13, 2026 addresses authorized healthcare facilities specifically. It requires covered hospitals, laboratories, medical centers, and dialysis centers to obtain TÜSKA accreditation by December 31, 2026. Other covered facility categories follow separate certification requirements. These regulatory requirements concern healthcare-service authorization and quality frameworks. They should not be interpreted as transplant success guarantees. Patients should verify current regulatory status while separately discussing medical suitability, donor selection, potential complications, informed consent, and continuing care with the transplant team.

Allogeneic Transplantation in Turkey Cost 2026: What Affects the Total Cost?

Allogeneic transplantation in Turkey has no single 2026 cost because donor and treatment requirements vary substantially between patients. This page therefore does not provide a fixed treatment price. HLA testing and donor searches can affect the financial plan. Unrelated or overseas donor coordination can create additional requirements. Stem cell collection, processing, conditioning medicines, hospitalization, and blood products also contribute. GVHD prevention, infection treatment, laboratory monitoring, and other supportive care can add further services. Complications cannot always be predicted before transplantation. International patients should request an individualized written quotation after medical and donor assessment, with included and excluded services clearly identified.

This content provides general medical information and does not recommend transplantation, a donor, healthcare provider, or clinical outcome. Allogeneic transplantation requires individualized assessment by appropriately qualified transplant professionals.

Last updated: August 14, 2026

Sources

• https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant

• https://www.cancer.gov/types/childhood-cancers/hp-stem-cell-transplant/allogeneic

• https://www.cancer.gov/types/childhood-cancers/hp-stem-cell-transplant/gvhd

• https://www.cancer.gov/news-events/cancer-currents-blog/2023/gvhd-prevention-stem-cell-transplant-cyclophosphamide

• https://www.cdc.gov/vaccines/hcp/imz-best-practices/altered-immunocompetence.html

• https://www.cdc.gov/yellow-book/hcp/travelers-with-additional-considerations/immunocompromised-travelers.html

• https://www.saglik.gov.tr/EN-50747/1000th-and-1001st-transplants-at-turkok.html

• https://ankarasehir.saglik.gov.tr/EN-834597/adult-bone-marrow-center.html

• https://ankarasehir.saglik.gov.tr/EN-835041/pediatric-bone-marrow-center.html

• https://shgmturizmdb.saglik.gov.tr/EN-69061/authorized-healthcare-providers-and-facilitators.html

• https://shgmturizmdb.saglik.gov.tr/EN-108974/regulation-on-international-health-tourism-and-tourist-health.html

• https://shgmturizmdb.saglik.gov.tr/TR-117812/saglik-turizmi-yetki-belgesine-sahip-saglik-tesislerinin-dikkatine.html

• https://antalyaism.saglik.gov.tr/TR-366500/saglik-hizmetlerinde-tanitim-ve-bilgilendirme--faaliyetleri-hakkinda-yonetmelik.html